Efzofitimod for early systemic sclerosis lung scarring
Part of Infections, Lungs & breathing, Skin clinical trials.
This trial tests efzofitimod to see if it can improve or slow lung disease caused by systemic sclerosis (scleroderma), and to check safety and side effects. It focuses on people with relatively early disease and measurable lung involvement on lung scans.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with systemic sclerosis (SSc) using the standard 2013 criteria
- Your systemic sclerosis started less than 84 months ago (from your first non-Raynaud symptom)
- Recent chest CT scan shows SSc-related interstitial lung disease with more than 10% lung involvement
- At screening, your condition fits limited or diffuse cutaneous systemic sclerosis
- You are taking a mycophenolate medicine (like MMF) at a sufficient dose and duration, or you can’t tolerate it but can take the best tolerated alternative immunosuppressant
- Your breathing tests show enough lung function (FVC must be >45% predicted, and DLco >30% predicted), and your FEV1/FVC ratio must be at least 0.7
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether mycophenolate mofetil (MMF) can slow or improve early, mild lung scarring in people with systemic sclerosis. It’s meant for systemic sclerosis patients who have lung involvement on a CT scan but still have good breathing test results.
This study tests whether a combination of two drugs, nintedanib and tocilizumab, can help people with systemic sclerosis (a condition that causes skin and organ hardening) who also have lung scarring (interstitial lung disease). The goal is to find a treatment that can slow down the disease.
This trial tests if a combination of three drugs (azithromycin, hydroxychloroquine, and prednisone) can help people with a genetic form of lung scarring. The goal is to see if these medicines calm the immune system and slow down the disease.
This study follows people with systemic sclerosis who also have lung scarring (interstitial lung disease). It aims to map how lung function and lung images change over time, which may help doctors predict and better manage disease progression.
This study helps doctors identify early signs of lung scarring (fibrosis) in patients with autoimmune diseases like scleroderma, rheumatoid arthritis, and Sjögren's syndrome. By catching this early, researchers hope to better understand and treat these complications.
This trial tests whether combining two drugs, rituximab and mycophenolate mofetil, is safe and works better than standard care for lung scarring caused by scleroderma. It may be an option if your lung disease is severe or getting worse.
Hear when a new Interstitial Lung Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.